Opinion|Videos|August 7, 2024

Perspectives on Indirect Comparisons of BTK Inhibitors for R/R CLL/SLL

Mazyar Shadman, MD, MPH, shares comprehensive insights on the latest analyses of zanubrutinib compared with other BTK inhibitors in relapsed/refractory CLL/SLL.

Video content above is prompted by the following question:

  • How do the latest analyses of zanubrutinib compare with other BTK inhibitors in relapsed/refractory CLL/SLL?

Latest CME